# Endo Paget Bisphosphonate Treatment Indication

> Recommends treatment with a bisphosphonate for most patients with active Paget's disease who are at risk of future complications. Triggers include active Paget's disease with risk of fracture, deformity, or neurologic symptoms.

- Skill: `dromlakhani/endo-paget-bisphosphonate-treatment-indication` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-paget-bisphosphonate-treatment-indication`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-paget-bisphosphonate-treatment-indication/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-paget-bisphosphonate-treatment-indication

---


# Initiate bisphosphonate for active Paget's disease at risk of complications

## STEP 1 — Gather Information
Confirm diagnosis of Paget's disease with plain radiographs of symptomatic areas and radionuclide bone scan to assess extent. Measure serum total alkaline phosphatase (ALP) or a specific bone turnover marker (P1NP, BSAP, CTx, NTx) to gauge activity. Evaluate for risk factors: history of fracture, bone deformity, neurologic symptoms (hearing loss, cranial nerve deficits, spinal stenosis). Assess renal function (eGFR) and vitamin D status to identify contraindications to IV zoledronate.

## STEP 2 — Rule In / Rule Out
If Paget's disease is confirmed (radiographic/scan evidence) AND the patient has at least one risk factor for complications (fracture, deformity, neurologic symptoms) → proceed to Step 3. Otherwise, do not initiate bisphosphonate therapy and consider observation.

## STEP 3 — Classify or Stratify
Assess suitability for IV zoledronate: 
- No contraindication (eGFR ≥35 mL/min, vitamin D sufficient) → classify as **IV zoledronate candidate**. 
- Contraindication present (eGFR <35 mL/min or vitamin D deficiency) → classify as **oral bisphosphonate candidate**.

## STEP 4 — Decide
- For IV zoledronate candidate: administer a single 5 mg intravenous infusion over 15 minutes; provide vitamin D supplementation if baseline 25‑OH‑vitamin D <30 ng/mL. 
- For oral bisphosphonate candidate: choose alendronate 40 mg daily for 6 months or risedronate 30 mg daily for 2 months; monitor GI tolerance.

## Clinical Guardrails / Mimics / Pitfalls
Do not treat asymptomatic patients lacking complication risk factors. Avoid IV zoledronate in severe renal impairment (eGFR <35 mL/min) without specialist consultation. Pre‑treat vitamin D deficiency to prevent hypocalcemia. Watch for acute phase reaction (flu‑like illness, uveitis) and manage with acetaminophen/NSAIDs prophylactically. Do not repeat radionuclide bone scans routinely to assess response; rely on clinical markers and symptoms. Avoid high‑dose etidronate due to osteomalacia risk.

## Concrete Clinical Example
A 70‑year‑old woman with known polyostotic Paget's disease (elevated ALP, bone scan widespread) reports increasing thigh pain and radiographic bowing of the femur. She has normal renal function (eGFR 68 mL/min) and vitamin D level 32 ng/mL. She is classified as an IV zoledronate candidate and receives a single 5 mg IV zoledronate infusion; symptoms improve over 3 months.

**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2910